Anna Moore, a researcher from Michigan State University’s Precision Health Program, discusses her groundbreaking work on targeting miR-10b to combat metastatic breast cancer. With a grim survival rate for this advanced stage, Anna highlights how inhibiting miR-10b can significantly impair the stem cell-like traits of cancer cells. She explains the potential of the nanodrug MN-anti in reducing miR-10b expression, suggesting innovative pathways for more effective therapies and a brighter outlook for patients.